References
- Ho D D, Rota T R, Schooley R T, Kaplan J C, Allan J D, Groopman J E, Resnick L, Felsenstein D, Andrews C A, Hirsch M S. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med 1985; 313: 1493–1497
- Chiodi F, Keys B, Albert J, Hagberg L, Lundeberg J, Uhlén M, Fenyö E-M, Norkrans G. HIV-1 is present in the cerebrospinal fluid of the majority of infected individuals. J Clin Microbiol 1992; 30: 1768–1771
- Sönnerborg A, Johansson B, Strannegård Ö. Detection of HIV-1 DNA and infectious virus in cerebrospinal fluid. AIDS Res Hum Retrovirus 1991; 7: 369–373
- Gisslén M, Chiodi F, Fuchs D, Norkrans G, Svennerholm B, Wachter H, Hagberg L. Markers of immune stimulation in the cerebrospinal fluid during HIV infection: A longitudinal study. Scand J Infect Dis 1994; 26: 523–533
- Portegies P, de Gans J, Lange J MA, Derix M MA, Speelman H, Bakker M, Danner S A, Goudsmit J. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. Br Med J 1989; 299: 819–821
- Portegies P, Enting R H, de Jong M D. Aids dementia complex and didanosine. Lancet 1994; 344: 759
- Hagberg L, Norkrans G, Andersson M, Wachter H, Fuchs D. Cerebrospinal fluid neopterin and β2-microglobulin levels in neurologically asymptomatic HIV-infected patients before and after initiation of zidovudine treatment. Infection 1992; 20: 313–315
- Brew B J, Bhalla R B, Morris P, Sidtis J J, Keilp J J, Sadler A E, Gallardo H, McArthur J C, Schwartz M K, Price R W. Cerebrospinal fluid β2-microglobulin in patients with AIDS dementia complex: an expanded series including responses to zidovudine treatment. AIDS 1992; 6: 461–465
- Center for Disease Control (CDC). 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1993; 41(RR-17)1–18
- Aurelius E, Forsgren M, Sköldenberg B, Strannegård Ö. Persistent intrathecal immunoactivation in patients with herpes simplex encephalitis. J Infect Dis 1993; 168: 1248–1252
- Hutterer J, Amburster C, Wallner G, Fuchs D, Vetter N, Wachter H. Early changes of neopterin concentrations during treatment of human immunodeficiency virus infection with zidovudine. J Infect Dis 1992; 165: 783–784
- Min Liu J, Fahey J L, Aziz N, Cumberland W G, Skowron G, Merigan T. Zidovudine and dideoxycytidine differ in their effects on human immunodeficiency virus-induced pathologic activation of the immune system. J Infect Dis 1994; 170: 1165–1171
- Bass H Z, Hardy W D, Mitsuyasu R T, Taylor J MG, Wang Y X, Fishl M A, Spector S A, Richman D D, Fahey J L. The effect of zidovudine treatment on serum neopterin and β2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals. J Aquir Imm Def Syndr 1992; 5: 215–221
- Vago L, Castagna A, Lazzarin A, Trabattoni G, Cinque P, Costanzi G. Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine. J Aquir Imm Def Syndr 1993; 6: 42–45
- Gray F, Bélec L, Keohane C, De Truchis P, Clair B, Durigon M, Sobel A, Gherardi R. Zidovudine therapy and HIV encephalitis: a 10-year neuropathological survey. AIDS 1994; 8: 489–493
- Mahlen J, Dunlop O, Liestol K, Dobloug H J, Goplen A K, Torvik A. Changing incidence of HIV-induced brain lesions in Oslo, 1983–1994: effects of zidovudine treatment. AIDS 1995; 9: 1171–1175
- Burger D M, Kraaijeveld C L, Meenhorst P L, Mulder J W, Koks C HW, Bult A, Beijnen J H. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993; 7: 1581–1587